Anifrolumab, a relatively recent monoclonal protein, is generating considerable hope within the healthcare community as a possible option for various autoimmune conditions. This unique medication targets the IFN receptor alpha chain, considerably reducing tissue damage that drives the progression

Camidanlumab, referred to as HuMax-TAC, represents a innovative therapeutic modality in the treatment of multiple cancers. This antibody selectively binds to TNF-alpha, a key cytokine implicated in tumor development and inflammation . Initial studies have revealed promising data, suggesting a sig